Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 158 matching trials from the live ClinicalTrials.gov search.
Conditions
Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Fluciclovine F18, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, X-Ray Imaging
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more
Conditions
Dexmedetomidine Induced Sedation
Interventions
dexmedetomidine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
Interventions
Computed Tomography, Iodine I 124, Iodine I-131, Laboratory Biomarker Analysis, Pharmacodynamic Study, Positron Emission Tomography, Trametinib
Procedure · Other · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Recruiting Phase 3 Interventional Accepts healthy volunteers

PSMA PET Combined With MRI for the Detection of PCa

NCT07052214
Conditions
PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET, Diagnostic Imaging, Elevated PSA, Positron Emission Tomography, Prostate Biopsy, Carcinoma of the Prostate
Interventions
68Ga-PSMA-11
Drug
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Boca Raton, Florida + 13 more
Conditions
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Lenalidomide, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography, Prednisone, Umbralisib, Vincristine Sulfate
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
429
States / cities
Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
Interventions
Obinutuzumab, Venetoclax, Magrolimab, Acetaminophen, Diphenhydramine, Prednisone/prednisolone, Methylprednisolone, CT Scan chest/abdomen/pelvis, MRI, 18-FDG-PET, Bone Marrow Biopsy, Bone Marrow Aspiration
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Positron Emission Tomography, Tuvusertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Bethesda, Maryland • Boston, Massachusetts • Mineola, New York + 2 more
Completed No phase listed Observational Accepts healthy volunteers

Multimodal Ocular Imaging in Neurodegeneration

NCT03699644
Conditions
Alzheimer Disease, Alzheimer Dementia, Frontotemporal Dementia
Interventions
Spectral-Domain Optical Coherence Tomography (SD-OCT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Comprehensive Ophthalmic Examination, Fundus Photography
Device · Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
45 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Prediabetes, Healthy (Controls)
Interventions
Ketone Monoester (KE), Placebo
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Pomalidomide, Quality-of-Life Assessment, Questionnaire Administration, Selinexor, X-Ray Imaging, Computed Tomography, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting Not applicable Interventional

Comparison of Whole Body DWI to FDG PET

NCT06630845
Conditions
Metastatic Cancer
Interventions
Fluorodeoxyglucose F18, Positron Emission Tomography combined with Magnetic resonance imaging (PET/MRI), Whole Body Magnetic Resonance Imaging with Diffusion-Weighted Imaging (WB-MRI-DWI), General Electric (GE) SIGNA PET/MR
Drug · Procedure · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma
Interventions
brentuximab vedotin, doxorubicin hydrochloride, vinblastine, dacarbazine, quality-of-life assessment, DNA analysis, RNA analysis, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis, immunohistochemistry staining method, polymorphism analysis
Drug · Procedure · Genetic + 2 more
Lead sponsor
Northwestern University
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
7
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Conditions
Colorectal Cancer
Interventions
chemotherapy, computed tomography, conventional surgery, neoadjuvant therapy, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Conditions
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lisocabtagene Maraleucel, Lymph Node Biopsy, Positron Emission Tomography, Zanubrutinib
Procedure · Drug · Biological
Lead sponsor
Aseel Alsouqi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio • Salt Lake City, Utah
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Aldesleukin, Computed Tomography, Entinostat, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography
Biological · Procedure · Drug + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Buffalo, New York + 1 more
Conditions
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET Scan, Sipuleucel-T
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Conditions
Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma
Interventions
Computed Tomography, Laboratory Biomarker Analysis, Pembrolizumab, Positron Emission Tomography, Recombinant EphB4-HSA Fusion Protein
Procedure · Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 5 more
Conditions
Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Durvalumab, Venetoclax, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Positron Emission Tomography (PET), Computed Tomography
Drug · Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Rituximab, Venetoclax
Procedure · Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT), Transurethral Resection of Bladder Tumor, Cystoscopy (CS), Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
Drug · Biological · Radiation + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Lymphoma, Extranodal Marginal Zone Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Nemtabrutinib, Positron Emission Tomography, Rituximab
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Conditions
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Hyperthermic Intraperitoneal Chemotherapy, Laparoscopy, Lymphadenectomy, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Surgical Procedure
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Active, not recruiting Phase 2 Interventional

PSMA PET Imaging of Recurrent Prostate Cancer

NCT03204123
Conditions
Prostate Adenocarcinoma, Prostate Cancer
Interventions
Ga-HBED-iPSMA PET, PET/CT, MRI
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1,171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Iberdomide, Belantamab Mafodotin, Dexamethasone, Echocardiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
43
States / cities
Ames, Iowa • Boone, Iowa • Fort Dodge, Iowa + 30 more